Literature DB >> 30104026

Corrigendum to "Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies" [J hepatol 67 (2017) 999-1008].

Jordi Bruix1, Ann-Lii Cheng2, Gerold Meinhardt3, Keiko Nakajima3, Yoriko De Sanctis3, Josep Llovet4.   

Abstract

Entities:  

Year:  2018        PMID： 30104026     DOI： 10.1016/j.jhep.2018.07.015

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  2 in total

1.  Effects of Radiotherapy on Survival of Esophageal Cancer Patients Receiving Immunotherapy: Propensity Score Analysis and Nomogram Construction.

Authors:  Yuanliu Nie; Guangyue Yao; Liang Li; Alei Feng; Wentao Zhang; Xiaoying Xu; Qiang Li; Zhe Yang
Journal:  Cancer Manag Res       Date:  2022-08-07       Impact factor: 3.602

2.  Prognostic factors and predictors of postoperative adjuvant transcatheter arterial chemoembolization benefit in patients with resected hepatocellular carcinoma.

Authors:  Ming-Yu Chen; Sarun Juengpanich; Jia-Hao Hu; Win Topatana; Jia-Sheng Cao; Chen-Hao Tong; Jian Lin; Xiu-Jun Cai
Journal:  World J Gastroenterol       Date:  2020-03-14       Impact factor: 5.742
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.